Couture EL, Lepage S, Masson JB, Daneault B. Very late transcatheter heart valve thrombosis. World J Cardiol 2017; 9(2): 196-199 [PMID: 28289535 DOI: 10.4330/wjc.v9.i2.196]
Corresponding Author of This Article
Benoit Daneault, MD, Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, 12e avenue nord, Sherbrooke J1H 5N4, Canada. benoit.daneault@usherbrooke.ca
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Feb 26, 2017; 9(2): 196-199 Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.196
Very late transcatheter heart valve thrombosis
Etienne L Couture, Serge Lepage, Jean-Bernard Masson, Benoit Daneault
Etienne L Couture, Serge Lepage, Benoit Daneault, Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke J1H 5N4, Canada
Jean-Bernard Masson, Division of Cardiology, Centre Hospitalier Universitaire de Montréal, Montréal H1P 2V8, Canada
Author contributions: All authors contributed to the acquisition of data, writing, and revision of this manuscript.
Institutional review board statement: This case report was exempt from the Institutional Review Board standards at Centre de recherche du centre hospitalier universitaire de Sherbrooke.
Informed consent statement: The patient involved in this study gave her written informed consent authorizing use and disclosure of her protected health information.
Conflict-of-interest statement: Dr. Masson is a proctor/consultant for Edwards Lifesciences Inc. All other authors have no conflicts of interests to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Benoit Daneault, MD, Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, 12e avenue nord, Sherbrooke J1H 5N4, Canada. benoit.daneault@usherbrooke.ca
Telephone: +1-819-3461110 Fax: +1-819-8206897
Received: June 12, 2016 Peer-review started: June 16, 2016 First decision: July 11, 2016 Revised: September 14, 2016 Accepted: November 16, 2016 Article in press: November 18, 2016 Published online: February 26, 2017
Abstract
We describe a case of very late transcatheter heart valve (THV) thrombosis of a first-generation SAPIEN prosthesis (Edwards Lifesciences, Irvine, CA) implanted in a 64-year-old woman with severe symptomatic aortic stenosis. More than 54 mo after implantation, she presented with severe symptomatic prosthesis dysfunction (stenosis) which was successfully treated with oral anticoagulation. To our knowledge, this is the tardiest case of THV thrombosis ever reported. This case should increase clinical awareness for THV thrombosis even beyond the first two-year period following implantation.
Core tip: We describe the tardiest case of transcatheter aortic valve replacement (TAVR) thrombosis ever reported. A 64-year-old woman with severe symptomatic aortic stenosis underwent TAVR with a first-generation SAPIEN prosthesis. More than four years (> 54 mo) following implantation, she presented with a severe symptomatic prosthesis dysfunction (stenosis) which was successfully treated with oral anticoagulation.
